Table 1.
Reported global annual product sales by calendar year for selected medicines according to company annual reports (2004–2017) (in million USD)a
| Year | Sovaldi® (sofosbuvir) Gilead [47] | Herceptin® (trastuzumab) Roche & Genentech [48] | Gleevec/Glivec® (imatinib) Novartis [49] |
|---|---|---|---|
| 2004 | N/A | 1162 | 1634 |
| 2005 | N/A | 1717 | 2170 |
| 2006 | N/A | 3142 | 2554 |
| 2007 | N/A | 4027 | 3050 |
| 2008 | N/A | 4736 | 3944 |
| 2009 | N/A | 4845 | 3944 |
| 2010 | N/A | 5212 | 4265 |
| 2011 | N/A | 5936 | 4659 |
| 2012 | N/A | 6301 | 4675 |
| 2013 | 139 | 6565 | 4693 |
| 2014 | 10,283 | 6840 | 1237 |
| 2015 | 5276 | 6800 | 1219 |
| 2016 | 4001 | 6918 | 3323 |
| 2017 | 964 | 7154 | 1943 |
| Total | 20,663 | 34,277 | 43,310 |
aAmounts rounded to millions. Trastuzumab sales have been converted from CHF to USD using historical exchange rates